Corpus ID: 13084296

Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.

@article{Knoll1994MultipleSD,
  title={Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.},
  author={J. Knoll and I. Miklya},
  journal={Archives internationales de pharmacodynamie et de therapie},
  year={1994},
  volume={328 1},
  pages={
          1-15
        }
}
  • J. Knoll, I. Miklya
  • Published 1994
  • Biology, Medicine
  • Archives internationales de pharmacodynamie et de therapie
  • As a measure of the basic activity of the catecholaminergic and serotoninergic systems, the biogenic amines released from freshly excised brain tissue were measured by means of HPLC with electrochemical detection. Rats of both sexes were injected subcutaneously, daily for 21 days, either with saline or with a dose of one of the enantiomers of the following compounds: deprenyl; p-fluorodeprenyl; 1-phenyl-2-propylaminopentane, a deprenyl analogue free of MAO-B inhibitory potency; methamphetamine… CONTINUE READING
    27 Citations
    The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.
    • P. Gaszner, I. Miklya
    • Medicine, Chemistry
    • Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology
    • 2004
    • 1
    • PDF
    Major depression and the synthetic enhancer substances, (−)-deprenyl and R-(−)-1-(benzofuran-2-yl)-2-propylaminopentane
    • P. Gaszner, I. Miklya
    • Chemistry, Medicine
    • Progress in Neuro-Psychopharmacology and Biological Psychiatry
    • 2006
    • 11
    Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline.
    • I. Miklya
    • Chemistry, Medicine
    • Pharmacological reports : PR
    • 2014
    • 6
    • PDF
    Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
    • J. Knoll
    • Medicine
    • Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
    • 1995
    • 26